Karyopharm Therapeutics (KPTI) Operating Leases (2019 - 2025)

Karyopharm Therapeutics has reported Operating Leases for 7 years, with the latest figure at $5.7 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases fell 14.44% year-over-year to $5.7 million; the trailing twelve-month figure through Dec 2025 stood at $5.7 million (down 14.44% YoY), and the FY2025 full-year result was $5.7 million, down 14.44% from the prior year.
• Operating Leases for Q4 2025 stood at $5.7 million, down from $6.0 million in the prior quarter.
• The five-year high for Operating Leases was $10.7 million in Q1 2021, with the low at $955000.0 in Q2 2024.
• Historically, Operating Leases has averaged $6.2 million across 5 years, with a median of $6.3 million in 2025.
• Annual changes were most pronounced in 2024 — Operating Leases slumped 78.78% — and 2025, when it surged 554.55%.
• Karyopharm Therapeutics' Operating Leases stood at $9.0 million in 2021, then sank by 32.02% to $6.1 million in 2022, then sank by 54.26% to $2.8 million in 2023, then surged by 140.66% to $6.7 million in 2024, then dropped by 14.44% to $5.7 million in 2025.
• The last three Operating Leases figures came in at $5.7 million (Q4 2025), $6.0 million (Q3 2025), and $6.3 million (Q2 2025), per Business Quant data.